Study of 5-Fluorouracil and High Dose Folinic Acid in Liver Cancer
Author Information
Author(s): A. Zaniboni, E. Simoncini, P. Marpicati, G. Marini
Primary Institution: Fondazione Beretta Spedali Civili
Hypothesis
The combination of 5-FU and high-dose folinic acid (HDFA) will improve treatment outcomes in nonresectable hepatocellular carcinoma (NHC) compared to 5-FU alone.
Conclusion
The combination of HDFA and 5-FU did not produce better results than 5-FU alone in treating NHC.
Supporting Evidence
- No response was seen in any of the 14 evaluable patients.
- 6 patients had stabilization of disease for a median duration of 82 days.
- Median survival was 98 days with no difference between stable or progressive disease.
Takeaway
Doctors tried a new medicine combination to help people with liver cancer, but it didn't work any better than the old medicine.
Methodology
14 untreated patients with NHC were treated with HDFA and 5-FU, and responses were evaluated after at least two cycles.
Limitations
The study had a small sample size and no responses were seen in any of the patients.
Participant Demographics
12 males and 2 females, median age 47.3 years.
Statistical Information
Confidence Interval
<20% at the 95% confidence interval
Want to read the original?
Access the complete publication on the publisher's website